The family of our target kinase proteins have 6 members. These targets play key roles in cellular signaling pathways that lead to the growth and metastasis of many cancers including brain tumors, breast cancer, colorectal cancer and pancreatic cancer, and thus become important targets in cancer treatment.

PAKINAX leverages its proprietary technology platform and expertise to discover and develop kinase inhibitors for different cancer and other diseases. Our lead product is PKX227 which is a highly selective kinase inhibitor and currently in pre-clinical animal study.